PhorMed, Inc. Our flagship technology, RP-323, is a revolutionary treatment that helps the body repair itself at the genetic level. By targeting neurological diseases, blood disorders, and inflammatory disorders like ARDS (Adult Respiratory Distress Syndrome), we are transforming the field of genomic medicine.

Our team of seasoned experts, including a dedicated management team and advisory board, is at the forefront of scientific innovation. We are committed to discovering new approaches to therapy that address the root causes of various diseases. Patient safety and well-being are our top priorities.

Through multiple clinical studies, RP-323 has been proven safe and effective. We are now preparing to enter the next phase of clinical trials in collaboration with two renowned clinical sites in Atlanta, Georgia. Investors can join us on this exciting journey and make a difference by investing in PhorMed through Equity Crowdfunding.

Together, we can revolutionize healthcare and improve the lives of countless patients. Contact us today to learn more about our pioneering work in genetic medicine